Estradiol/levonorgestrel sequential transdermal - Merck KGaA
Alternative Names: EMD-59265; Fem7 CombiLatest Information Update: 24 Oct 2021
At a glance
- Originator Merck KGaA
- Class Estradiol congeners; Estrenes; Hormonal replacements; Norpregnanes; Small molecules
- Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Menopausal syndrome
Most Recent Events
- 05 Jul 2019 Chemical structure information added
- 31 Dec 2002 Fem7® Combi has been licensed to Gedeon Richter in many Central European, Eastern European and Commonwealth of Independent States countries
- 27 May 2002 A study has been added to the adverse events and Women's Health therapeutic trials sections